434 related articles for article (PubMed ID: 9443397)
21. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
22. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ
Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063
[TBL] [Abstract][Full Text] [Related]
23. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D; Liu Y; Yang P; Chen Y; Tian Y
Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
[TBL] [Abstract][Full Text] [Related]
24. von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.
Danilin S; Sourbier C; Thomas L; Rothhut S; Lindner V; Helwig JJ; Jacqmin D; Lang H; Massfelder T
Carcinogenesis; 2009 Mar; 30(3):387-96. PubMed ID: 19056930
[TBL] [Abstract][Full Text] [Related]
25. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD
Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082
[TBL] [Abstract][Full Text] [Related]
26. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
Pause A; Lee S; Lonergan KM; Klausner RD
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):993-8. PubMed ID: 9448273
[TBL] [Abstract][Full Text] [Related]
27. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
[TBL] [Abstract][Full Text] [Related]
28. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
[TBL] [Abstract][Full Text] [Related]
29. Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity.
Caldwell MC; Hough C; Fürer S; Linehan WM; Morin PJ; Gorospe M
Oncogene; 2002 Jan; 21(6):929-36. PubMed ID: 11840338
[TBL] [Abstract][Full Text] [Related]
30. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
31. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
32. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
33. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis.
Schoenfeld AR; Parris T; Eisenberger A; Davidowitz EJ; De Leon M; Talasazan F; Devarajan P; Burk RD
Oncogene; 2000 Nov; 19(51):5851-7. PubMed ID: 11127815
[TBL] [Abstract][Full Text] [Related]
34. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
35. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
[TBL] [Abstract][Full Text] [Related]
36. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.
Cohen HT; Zhou M; Welsh AM; Zarghamee S; Scholz H; Mukhopadhyay D; Kishida T; Zbar B; Knebelmann B; Sukhatme VP
Biochem Biophys Res Commun; 1999 Dec; 266(1):43-50. PubMed ID: 10581162
[TBL] [Abstract][Full Text] [Related]
37. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
38. Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma.
Maranchie JK; Zhan Y
Cancer Res; 2005 Oct; 65(20):9190-3. PubMed ID: 16230378
[TBL] [Abstract][Full Text] [Related]
39. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
40. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]